Posted by Michael Wonder on 08 Jun 2017
Institute for Clinical and Economic Review's final report on treatments for atopic dermatitis provides policy recommendations to support appropriate patient access to dupilumab
8 June 2017 - Report analyses evidence on the comparative effectiveness of dupilumab, finds price well-aligned with added value for patients; recommendations highlight coverage considerations and actions for all stakeholders to improve evidence, ensure appropriate access, and manage affordability.
The ICER has issued a final evidence report and summary of a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) that concludes that dupilumab (Dupixent, Regeneron and Sanofi) offers good long-term value for patients with moderate-to-severe atopic dermatitis.
The report, along with an accompanying Report-at-a-Glance, also assesses the comparative clinical effectiveness of crisaborole (Eucrisa, Pfizer) for mild-to-moderate disease.
